CD8A and neoplasm: In the neoadjuvant setting, the activation of immune cells, including NK, CD4+, and CD8+ T cells, at the primary site and increases in the numbers of peripheral immune cells, including pNK and CD8+ T cells, in the blood were observed after NAC, regardless of tumor subtype [81,82].